Pricing of CNH Industrial Capital LLC $500 million notes
Basildon, September 11, 2023
CNH Industrial N.V. (NYSE: CNHI / MI: CNHI) today announced that its wholly owned subsidiary, CNH Industrial Capital LLC, has priced $500 million in aggregate principal amount of 5.500% notes due 2029, with an issue price of 99.399%. The offering is expected to close on September 13, 2023, subject to the satisfaction of customary closing conditions.
CNH Industrial Capital LLC intends to add the net proceeds from the offering to its general funds and use them for working capital and other general corporate purposes, including, among other things, the purchase of receivables or other assets in the ordinary course of business. The net proceeds may also be applied to repay CNH Industrial Capital LLC’s indebtedness as it becomes due.
The notes, which are senior unsecured obligations of CNH Industrial Capital LLC, will pay interest semi-annually on January 12 and July 12 of each year, beginning on January 12, 2024, and will be guaranteed by CNH Industrial Capital America LLC and New Holland Credit Company, LLC, each a wholly owned subsidiary of CNH Industrial Capital LLC. The notes will mature on January 12, 2029.
RBC Capital Markets, LLC, J.P. Morgan Securities LLC, Santander US Capital Markets LLC and Wells Fargo Securities, LLC are acting as joint book-running managers and the representatives of the underwriters for the offering, and Intesa Sanpaolo IMI Securities Corp., NatWest Markets Securities Inc., SG America Securities, LLC and UniCredit Capital Markets LLC are acting as joint book-running managers for the offering. The offering is being made pursuant to an effective shelf registration statement filed with the U.S. Securities and Exchange Commission on March 14, 2022. Copies of the prospectus supplement and the accompanying prospectus for the offering may be obtained by contacting RBC Capital Markets, LLC, Attn: Syndicate Operations, 200 Vesey Street, 8th Floor, New York, NY 10281, Telephone: 1-866-375-6829, Email: rbcnyfixedincomeprospectus@rbccm.com; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, Attn: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, Telephone: 1-866-803-9204; Santander US Capital Markets LLC, 437 Madison Avenue, 10th floor, New York, NY 10022, Telephone: 1-855-403-3636, Email: DCMAmericas@santander.us; or Wells Fargo Securities, LLC, 608 2nd Avenue South, Suite 1000, Minneapolis, MN 55402, Attn: WFS Customer Service, Email: wfscustomerservice@wellsfargo.com, Toll-Free: 1-800-645-3751. Copies of the prospectus supplement and the accompanying prospectus for the offering are also available on the website of the U.S. Securities and Exchange Commission at http://www.sec.gov.
***
This press release does not constitute an offer to sell or a solicitation of an offer to buy any of these securities, nor shall there be any sale of these securities, in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful.
CNH Industrial Capital LLC is an indirect wholly owned subsidiary of CNH Industrial N.V. and is headquartered in Racine, Wisconsin. As a captive finance company, the primary business of CNH Industrial Capital LLC and its subsidiaries is to underwrite and manage financing products for end-use customers and dealers of CNH Industrial America LLC and CNH Industrial Canada Ltd. (collectively, “CNH Industrial North America”) and provide other related financial products and services to support the sale of agricultural and construction equipment sold by CNH Industrial North America. CNH Industrial Capital LLC and its subsidiaries also provide wholesale and retail financing related to new and used agricultural and construction equipment manufactured by entities other than CNH Industrial North America. CNH Industrial Capital LLC’s principal executive offices are located at 5729 Washington Avenue, Racine, WI 53406, and the telephone number is +1(262) 636-6011.
Contacts:
Media Relations
Email: mediarelations@cnhind.com
Investor Relations
Email: investor.relations@cnhind.com
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Changes in Sampo Group Executive Committee and Board of Directors1.10.2023 11:05:00 CEST | Press release
SAMPO PLC STOCK EXCHANGE RELEASE 1 October 2023 at 12:05 pm Changes in Sampo Group Executive Committee and Board of Directors Following the completion of the partial demerger of Sampo plc, the Sampo Group Executive Committee (GEC) terms of Patrick Lapveteläinen, former Sampo Group CIO, and Petri Niemisvirta, CEO of Mandatum, have ended. Meanwhile, the new Sampo Group CIO Ville Talasmäki has joined the GEC today. Lapveteläinen and Niemisvirta have moved to Mandatum plc, a new company established in connection with the demerger to take up roles as Full-time Chair of the Board and CEO, respectively. Both Patrick Lapveteläinen and Petri Niemisvirta were members of Sampo GEC since 2001. Following the changes, the strength of the GEC has decreased from seven to six members. As previously communicated, the number of the members of the Board of Directors of Sampo has declined from ten to nine as Johanna Lamminen has left the Board as of today. Lamminen, who has been a member of the Sampo Board
Partial demerger of Sampo completed - Mandatum to be listed on Nasdaq Helsinki1.10.2023 11:00:00 CEST | Press release
SAMPO PLC STOCK EXCHANGE RELEASE 1 October 2022 at 12:00 pm NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA OR SINGAPORE OR ANY OTHER JURISDICTION IN WHICH PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. Partial demerger of Sampo completed - Mandatum to be listed on Nasdaq Helsinki The completion of Sampo plc’s partial demerger has today been registered with the Finnish Trade Register and Mandatum has consequently been separated from Sampo Group, in accordance with the decision of Sampo’s Annual General Meeting on 17 May 2023. Nasdaq Helsinki has admitted the shares in Mandatum plc, the company incorporated in the demerger, to trading on the official list from 2 October 2023. - By separating Mandatum from Sampo, we have simplified the Group and created two entities that are well placed to create shareholder value. Sampo becomes a pure P&C insurance group, while Mandatum i
Redomiciliation to Bermuda completed30.9.2023 16:28:35 CEST | Press release
The Hague, September 30, 2023 - Aegon’s Extraordinary General Meeting of shareholders (EGM) today approved the cross-border conversion into a Bermuda Limited company. After the completion of the EGM, the change of Aegon’s legal seat to Bermuda has been effectuated, as a result of which the company became a Bermuda entity: Aegon Ltd. As of October 1, 2023, the Bermuda Monetary Authority will be Aegon’s group supervisor. Aegon shares will continue to be listed on Euronext Amsterdam (AGN) and NYSE (AEG). As at market open on October 2, 2023, trading will commence in Aegon Ltd. shares. The identifiers (such as the ISIN) of the Aegon shares will change: the Aegon Ltd. common shares will have the ISIN BMG0112X1056; andthe Aegon Ltd. common shares held in New York registry form will have the ISIN US0076CA1045 and the CUSIP 0076CA 104.1 More information on the redomiciliation, as well as the documentation relating to it, can be found here. Contacts Media relations Investor relations Richard Ma
Vow ASA: Order received to double production capacity at VGM’s Follum factory30.9.2023 12:00:00 CEST | Press release
On September 30th, 2023, Vow ASA announced that it has received an order from Vow Green Metals AS to enhance the production capacity at their biocarbon production plant in Hønefoss, Norway. This order is an extension of the equipment order received in October 2021, resulting in a new total contract value of NOK 332 million. In addition to some modification on the original equipment order, the expansion will involve the addition of a new process line, effectively doubling the factory's capacity. This will enable the production of up to 20,000 tons of biocarbon annually. The increased capacity is made possible by utilizing self-sufficient renewable gas to power the new reactor technology developed and manufactured by Vow's subsidiary, C. H. Evensen Industriovner AS. This ensures that the expanded capacity remains within the site's power supply limits. Henrik Badin, CEO of Vow ASA, expressed enthusiasm for this solution, emphasizing its ability to enhance efficiency, significantly increas
FDA Approves Biogen’s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®29.9.2023 22:06:00 CEST | Press release
TOFIDENCE (BIIB800) becomes the first tocilizumab biosimilar to gain FDA approval in the United States FDA approval is based on a robust analytical, non-clinical and clinical data package comparing TOFIDENCE to the reference product ACTEMRA CAMBRIDGE, Mass., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that the U.S. Food and Drug Administration (FDA) has approved TOFIDENCE (tocilizumab-bavi) intravenous formulation, a biosimilar monoclonal antibody referencing ACTEMRA. The TOFIDENCE intravenous formulation is approved for the treatment of moderately to severely active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and systemic juvenile idiopathic arthritis. TOFIDENCE is the first tocilizumab biosimilar approved in the United States. Biosimilars are biologic products that have been demonstrated to have equivalent efficacy and comparable safety as the approved reference product, with the advantage that they may offer cost savings and promote